^
No biomarker
Melanoma
pembrolizumab
Sensitive
:
A1
Merck (MSD) Press Release - 2 weeks - (New A1)
PD-L1 underexpression
Melanoma
nivolumab / relatlimab
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 1 week - (New A1)
BRAF V600
Melanoma
encorafenib + binimetinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Melanoma
vemurafenib + cobimetinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Melanoma
pembrolizumab
Sensitive
:
A1
J Am Acad Dermatol - 3 weeks - (New C3)
PD-L1 expression
Melanoma
pembrolizumab
Sensitive
:
B
ESMO 2022 - 3 weeks - (New B)
BRAF mutation
Melanoma
encorafenib + binimetinib
Sensitive
:
C2
Cancer Treat Rev - 3 weeks - (New C3)
PAK4 overexpression
Melanoma
Immunotherapy
Resistant
:
C3
ESMO 2022 - 3 weeks - (New C3)
PMS2 mutation
Melanoma
Immunotherapy
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
KIT mutation
Melanoma
imatinib + toripalimab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Melanoma
vorinostat
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HLA-A*02:01
Uveal Melanoma
ipilimumab + tebentafusp
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
CDK4 amplification
Mucosal Melanoma
dalpiciclib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
No biomarker
Basal Cell Carcinoma
fluorouracil topical
Sensitive
:
A1
BRAF V600
Melanoma
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600E
Melanoma
dabrafenib
Sensitive
:
A1
BRAF V600E
Melanoma
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600K
Melanoma
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600E
Melanoma
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600E
Melanoma
vemurafenib
Sensitive
:
A1
BRAF V600E
Melanoma
trametinib
Sensitive
:
A1
No biomarker
Melanoma
nivolumab
Sensitive
:
A1
No biomarker
Basal Cell Carcinoma
vismodegib
Sensitive
:
A1
No biomarker
Merkel Cell Carcinoma
avelumab
Sensitive
:
A1
No biomarker
Merkel Cell Carcinoma
pembrolizumab
Sensitive
:
A1
No biomarker
Basal Cell Carcinoma
imiquimod
Sensitive
:
A1
No biomarker
Melanoma
ipilimumab
Sensitive
:
A1
No biomarker
Melanoma
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 underexpression
Melanoma
ipilimumab
Sensitive
:
A1
PD-L1 underexpression
Melanoma
nivolumab + ipilimumab
Sensitive
:
A1
BRAF V600
Melanoma
dabrafenib
Sensitive
:
A1
No biomarker
Melanoma
trametinib
Resistant
:
A1
BRAF V600
Melanoma
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
trametinib
Sensitive
:
A1
BRAF V600K
Melanoma
trametinib
Sensitive
:
A1
BRAF V600
Melanoma
vemurafenib
Sensitive
:
A1
No biomarker
Basal Cell Carcinoma
sonidegib
Sensitive
:
A1
No biomarker
Cutaneous Melanoma
ipilimumab
Sensitive
:
A1
BRAF V600K
Melanoma
encorafenib + binimetinib
Sensitive
:
A1
BRAF V600E
Melanoma
encorafenib + binimetinib
Sensitive
:
A1
BRAF V600K
Melanoma
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600
Melanoma
nivolumab
Sensitive
:
A1
No biomarker
Basal Cell Carcinoma
cemiplimab
Sensitive
:
A1
LDH elevation
Melanoma
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Melanoma
aldesleukin
Sensitive
:
A1